Document is current
Any future updates will be listed below
-
Authors
Lan, Ting
Tang, Tao-Tao
Di, Jing-Jing
Qin, Suo-Fu
Muzaipaier, Aihemaiti
Zhou, Qin-Yu
Liu, Bi-Cheng
Wu, Qiu-Li
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82200772)
Natural Science Foundation of Jiangsu Province grant (BK20220828)
Fundamental Research Funds for the Central Universities (2242023R40030)
Start-up Research Fund of Southeast University (RF1028623235)
Shenzhen Science and Technology Project (KJZD20230923115201003)
the Joint Innovation Laboratory for the Industrialization of Extracellular Vesicle-Based Drug Delivery Technology Established by Shenzhen Kexing Pharmaceutical Co., Ltd. and Southeast University (8524006050)
the National Natural Science Foundation of China (82230022)
- License Information
-
More Information
Article History
Received: 19 June 2025
Accepted: 2 July 2026
First Online: 8 July 2026
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki. Primary MSCs were isolated from the human umbilical cord as previously described. All donors provided their informed consent. The use of human umbilical cord-derived mesenchymal stem cells was approved by the Clinical Research Ethics Committee of Zhongda Hospital, Southeast University under the project entitled “Mechanistic study on the remodeling of the renal tubulointerstitial inflammatory microenvironment by human umbilical cord mesenchymal stem cell-derived extracellular vesicles” (approved on 11 May 2023, No. 2023ZDSYLL118-P01). All experiments involving animals were approved by the Ethics Committee of Southeast University under the project entitled “Mechanistic study on the remodeling of the renal tubulointerstitial inflammatory microenvironment by human umbilical cord mesenchymal stem cell-derived extracellular vesicles” (approved on 24 February 2022, No. 2022450).
: Not applicable.
: The authors declare no competing interests.
